Results 111 to 120 of about 25,067 (205)
Alimentary Pharmacology &Therapeutics, Volume 64, Issue 1, Page 103-111, July 2026.In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi +8 more
wiley +1 more source
Olaparib za zdravljenje raka jajčnikov
, 2019 Olaparib vam je zdravnik predpisal, ker gre pri vas za ponovitev bolezni in imate ugotovljeno mutacijo v genih BRCA 1 ali BRCA 2 (izraz BRCA je kratica, ki v slovenskem prevodu pomeni „gen dovzetnosti za pojav raka dojk“).
Škof, Erik
core
Olaparib‐associated cutaneous vasculitis in a patient with breast cancer
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca +3 more
wiley +1 more source
Cancer Science, Volume 117, Issue 7, Page 1852-1866, July 2026.In hepatocellular carcinoma, the 8q24.3 locus is frequently amplified and is associated with tumor‐specific overexpression of TONSL. TONSL promotes homologous recombination repair through RAD51, limits γH2AX accumulation and apoptosis, supports tumor growth, and its loss increases sensitivity to poly (ADP‐ribose) polymerase (PARP) inhibition.
Akinori Tsujimoto +16 more
wiley +1 more source
Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.Integrated physical and virtual modeling provides a scalable framework to overcome sample scarcity, recapitulate mucosal melanoma biology, and accelerate translational discovery toward precision medicine. ABSTRACT Mucosal melanoma (MM) is a rare and lethal subtype of melanoma, disproportionately affecting Asian populations and exhibiting distinct ...
Xiangjie Jin +4 more
wiley +1 more source
Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects
Ruihua Dong,1,* Jingcheng Chen,1,* Nini Guo,2 Yingying Yang,2 Jingxuan Wu,1 Xiaoru Wang,2 Yuqin Song,1 Xueyuan Zhang2 1Phase I Clinical Trial Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China;
Guo N +7 more
core
Olaparib elicits an increase in TRAIL receptor 2 (DR5) expression in GBM cells.
, 2014 A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B–D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (
Peter Canoll (220255) +9 more
core +1 more source
SPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway
Cell Death DiscoveryPARPis resistance is a challenge in the treatment of ovarian cancer. To investigate the potential mechanism involved in olaparib resistance of ovarian cancer, high-throughput sequencing was performed on olaparib-resistant SKOV3 cell line named SK/Ola ...
Kai Teng +4 more
doaj +1 more source
Cancer Cell InternationalPurpose We tested whether the PARP inhibitor, Olaparib, can effectively enhance radiosensitivity while inhibiting OSCC growth and metastasis in vitro and in vivo. Patient samples were used for survival validation.
Chih-Chia Yu +12 more
doaj +1 more source
PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells [PDF]
SIGNIFICANCE: Olaparib, a PARP inhibitor, is effective against various cancers, including prostate cancer. However, resistance to olaparib poses a significant challenge.
Sharifi, Masuda +11 more
core +1 more source